Search is Powered by Google
Breast Cancer News

Disparities Found In Use Of Less-Invasive Breast Cancer Staging Test

Main Category: Breast Cancer
Article Date: 26 Mar 2008 - 4:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:3 stars

3 (1 votes)

Health Professional:not yet rated

Article Opinions: 0 posts

The use of sentinel lymph node biopsy (SLNB) during breast cancer surgery increased substantially from 1998 through 2005, according to an article published online March 25 in the Journal of the National Cancer Institute. However, non-white women, older women, and those living in poorer areas of the U.S. were less likely to receive SLNB than their counterparts who are white, younger, or from more affluent areas, respectively.

A key prognostic factor for breast cancer is whether or not the disease has spread beyond the breast tissue into neighboring lymph nodes. To look for such invasion, surgeons can remove many lymph nodes in a procedure called axillary lymph node dissection (ALND) or only a few in the SLNB procedure. In 1998, clinical care guidelines changed, allowing surgeons to use SLNB for certain patients. SLNB is associated with easier recovery and fewer long-term problems for patients than ALND.

In the current study, Amy Y. Chen, M.D., of Emory University and the American Cancer Society in Atlanta and colleagues examined patient data from a national hospital-based cancer registry to determine how frequently SLNB had been used between 1998 and 2005. They also looked at whether patient-related factors or the type of treatment facility affected a woman's chance of receiving SLNB over ALND.

The researchers identified 490,899 women in the National Cancer Database who underwent breast cancer surgery during the study period and had a stage of disease for which SLNB would be appropriate. The proportion of these patients who underwent SLNB increased from 26.8 percent to 65.5 percent during the study period. However, not all women were equally likely to undergo SLNB. Non-white women, women aged 72 years or older, and those who lived in zip code areas that had a lower proportion of high school graduates or lower median incomes were less likely than women who were white, younger, or from more educated or affluent regions to undergo SLNB. Disparities between these groups persisted from 1998 through 2005. For example, in 1998, 29 percent of white women received SLNB, compared with 26 percent among African American women and 35 percent among Hispanic women. In 2005, these rates rose to 70 percent, 64 percent, and 67 percent, respectively.

The clinical guidelines recommend that SLNB only be performed in facilities that have teams experienced with the procedure. While the use of SLNB increased over time in all types of hospitals, data were not available to assess whether disparities in access to SLNB were related to lack of experience with the procedure in facilities that were treating poorer women.

"The disparities that were related to receipt of SLNB in this study are particularly important in light of the clinical advantages associated with this technique. Better outcomes have been reported for patients receiving SLNB than for patients receiving ALND," the authors write.

In an accompanying editorial, Stephen B. Edge, M.D., of Roswell Park Cancer Institute in Buffalo, N.Y., describes the history of sentinel lymph node biopsy and its rapid acceptance among breast cancer surgeons. The incorporation of the technique preceded outcome data from large randomized trials. In this instance, such enthusiasm appears to have been well placed, he writes, but a more cautious approach with new interventions should be observed in general.

Despite the eagerness of surgeons to use the technique, not all patients have equal access to the less invasive approach. "Given America's track record of disparate care, I suppose we should not be surprised that racial and ethnic minorities were disproportionately deprived of another medical advance. However, this observation is profoundly disappointing and sobering. It is yet another call for us to redouble efforts to identify and correct the root causes of disparities," Edge writes.

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

Citation:

* Article: Chen AY, Halpern MT, Schrag NM, Stewart A, Leitch M, Ward E. Disparities and Trends in Sentinel Lymph Node Biopsy Among Early-Stage Breast Cancer Patients (1998 - 2005). J Natl Cancer Inst 2008; 100:462-474

* Editorial: Edge SB. Early Adoption and Disturbing Disparities in Sentinel Node Biopsy in Breast Cancer. J Natl Cancer Inst 2008; 100:449-450

The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Visit the Journal online at http://jnci.oxfordjournals.org/.

Source: Liz Savage
Journal of the National Cancer Institute


Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Understanding And Treating Triple-Negative Breast Cancer
07 Jan 2009
Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile...


Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

Breast Cancer Treatment: Get Involved image Breast Cancer Treatment: Get Involved

Today, breast cancer patients may be treated by a multidisciplinary team of specialists, consisting of nurses, oncologists, surgeons, social workers, nutritionists and genetic counselors. However, patients, too, have a critical role in their treatment...

View more videos...